The Boom In Women Infertility Market

Date: 27-Mar-2015
Infertility is an abnormality in the regular functioning of the human reproductive system. Anyone of male or female might be suffering from this issue. Infertility in woman is caused by either a genetical factor or factors such as aging or a cause resulting from the lifestyle of the person. There are many ways in which infertility in woman can be treated. Scientists and researchers have come up with ideas and technology that can be used to help couples become parents. There are different medications available along with diagnosis process that one can try. Many a times the treatments can be funded by national health organisations of the respective country or states however one wouldn’t want to opt for such a facility as the waiting period is too long.

Referring to the Women Infertility – Pipeline Review, H1 2015 (http://www.rnrmarketresearch.com/women-infertility-pipeline-review-h1-2015-market-report.html) one gets a clear understanding of the development of Women Infertility  market including a detailed analysis of drug target, mechanism of action (MoA), route of administration (RoA) and molecule type together with the latest updates. It includes a detailed anlysis of 44 players of the market. Some them are- Actavis plc, AstraZeneca PLC, Bayer AG, Crinetics Pharmaceuticals, Inc., Evotec AG, Finox AG, GlaxoSmithKline plc, Isifer AB, Kissei, Pharmaceutical Co., Ltd., Lipicard Technologies Limited, Merck & Co., Inc., Philogen S.p.A., Reliance Life Sciences Pvt. Ltd. And Zydus Cadila Healthcare Limited. The report also includes drug profile of 84 different types of drugs. Some of them being ADX-68692, Biosimilar 4 for Acute Myocardial Infarction and Infertility, corifollitropin alfa, DR-2011, Endole , follitropin alfa, goserelin biosimilar, Isifera, KLH-2109, LT-6121, Monoclonal Antibody to Antagonize Prolactin Receptor for Endometriosis, NCE-403 Oral Fertility Drugs, Peptides for Cancer and Endometriosis, RTPR-013 and VPE-001.

There are a number of clinics which offer therapeutic services for this problem. It has been noted that there is an increasing trend wherein every one out of seven women suffer from infertility. Presently this services industry is booming with opportunities as the demand of the services increase the offer sky-rocket at the same rate. The overall service market of overcoming infertility is estimated to grow at a rate of 3.6% every year of this 2% is contributed by vitro fertilization (IVF) services or what we popularly know as test-tube baby services. As per Marketdata, the research firm, this market is expected to be value d at $4 billion by 2018. There are many activities on-going in global platform for correcting infertility among women. Players in the market are investing in upgrading its R&D unit, building strategies to overcome competition.

A person referring to Global Markets Direct’s report on Women Infertility will be able to devise his R&D development strategies as it includes significant competitor information, analysis and valuable insights. The report mentions the new entrants to the market and the emerging players. The report also helps in  developing and designing in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. It includes a list of discontinued and projects that has been postponed. The information included in the report has been extracted from annual reports/SEC filings, proprietary databases belonging to Global Markets Direct, Company/University portals and other third party sources.